NICE endorses alitretinoin use

Patients with severe chronic hand eczema who have run out of treatment options can now be considered for treatment with alitretinoin (Toctino), according to new guidance issued by NICE.

Alitretinoin, an orally administered retinoid, is recommended for adults whose disease has not responded to potent topical corticosteroids. Eligible patients must also have a dermatology life quality index (DLQI) score of 15 or more.

Treatment with alitretinoin should be stopped:

  • when an adequate response (hands clear or almost clear) is achieved.
  • if eczema remains severe after 12 weeks.
  • if an adequate response is not achieved by 24 weeks.

Disease is considered ‘severe' if defined as such by the physician's global assessment (PGA).

Only physicians who are experienced in both the management of severe chronic hand eczema and the use of systemic retinoids should start and monitor treatment with alitretinoin.

View Toctino drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases